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Abstract
Controversies abound in the areas of blood transfusion, albumin,
lipoproteins in sepsis and pulmonary artery catheters. We are also
making too many errors, but at least there is a new nitric oxide
therapy in the offing.
How to deliver oxygen?
The delivery of oxygen to tissues remains a central tenet of
intensive care medicine. Much of the attention has focused
on optimizing cardiac output and perfusion pressure, not
least because we possess therapeutic tools that affect these
parameters. The second element in the equation is oxygen
carrying capacity, which is primarily determined by haemo-
globin concentration and hence red cell mass. Transfusion of
stored red blood cells is used to maintain oxygen carrying
capacity, although the optimal use of this therapy remains an
area of considerable controversy. It is well established that
transfused red blood cells carry but do not efficiently release
oxygen for at least 24 hours, because of 2,3-diphospho-
glycerate depletion. In addition, they do not deform to
facilitate transit through the microcirculation. Use of a low
transfusion threshold has been shown to be of benefit [1], as
has a more permissive approach [2]. Habib and colleagues
[3] have added to this controversy in their detailed study of
the effects of anaemia and red blood cell transfusion in
patients undergoing cardiopulmonary bypass. They measured
changes in renal function as an index of end-organ damage
due to impaired tissue oxygen delivery. The results, which are
eloquently discussed in an accompanying editorial [4],
demonstrate renal injury caused both by anaemia and
transfusion. In the words of the editorialist, ‘damned if you
do/damned if you don’t!’
However, a recent animal study may yet offer us some
salvation. Young and colleagues have been developing a
substitute for red blood cell transfusion by conjugating
haemoglobin tetramers with polyethylene glycol (PEG). In their
most recent paper [5] they resuscitated a pig model of
intraoperative haemorrhagic shock with a single, small volume
bolus of Ringer’s acetate, 10% pentastarch, 4 g/dl stroma-free
haemoglobin, or their PEG-conjugated human haemoglobin.
The animals then received an autologous blood transfusion,
the blood having been removed as the first of two insults, the
second being an aortic tear that was surgically controlled after
30 min. Six of the seven animals that received the PEG-
conjugated human haemoglobin survived, as compared with
only two of the seven that received the Ringer’s acetate, two
of the seven that received the stroma-free haemoglobin, and
one of the seven that received the pentastarch. Survival was
predicted by the trends in physiological parameters monitored.
In their discussion, the authors emphasized that maintenance
of oxygen carrying capacity as well as functional capillary
density, by preserving blood viscosity, are essential if fatal
tissue hypoxia is to be prevented. Further insightful comments
also appear in an editorial concerning the importance of blood
viscosity [6]. Human trials of this alternative intervention are
keenly awaited.
A further consideration in increasing oxygen delivery is the
fraction of inspired oxygen. In a well argued hypothesis piece,
Iscoe and Fisher [7] remind us that oxygen is a respiratory
stimulant; thus, administering 100% oxygen results in
hyperventilation with consequent hypocapnia and regional
vasoconstriction. The net effect, they suggest, will in fact be a
reduction in oxygen delivery to a wide variety of vascular beds
caused by disadvantageous changes in the microcirculation.
This adds further credence to maintaining normocapnia or
even mild hypercapnia in patients with borderline tissue
perfusion and actively monitoring this parameter. By the same
token, aiming for normoxia, as opposed to hyperoxia, is
probably desirable.
Albumin: SAFE, but useful or predictable?
Editorials often reflect on the fashionable nature of a wide
variety of intensive care unit (ICU) interventions. The use of
albumin is a classic example, with a series of contradictory
meta-analyses [8-11] and a recent large scale, prospective,
multicentre trial [12]. Given the available evidence base,
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few would dispute that albumin is safe but the evidence for
its efficacy remains limited. Two new studies are worthy of
note.
Martin and colleagues [13] presented their second
interventional study into the efficacy of albumin-supported
diuresis in the nonacute phase of acute lung injury (ALI) in
patients with hypoproteinaemia. This group previously
reported an observational study establishing a link between
hypoproteinaemia and poor outcome in ALI [14]. They then
went on to conduct a randomized controlled trial of albumin
and furosemide versus placebo in a small group of
hypoproteinaemic patients with ALI [15]. They demonstrated
short-term improvements in fluid balance, oxygenation and
haemodynamics in the treatment group.
To establish whether the combination or furosemide alone
was superior, they conducted this follow-up study [13]. They
randomized a heterogeneous group of patients with ALI to
receive 72 hours of continuous, low-dose furosemide with
either 8 hourly boluses of 25% albumin or 0.9% saline
(placebo). They successfully recruited 20 patients into each
arm and measured both short-term physiological effects
together with longer term clinical outcomes, although the
study was not powered to detect meaningful differences in
the latter. The treatment group achieved greater cumulative,
negative fluid balance at 72 hours (–5480 ml versus
–1490 ml;  P < 0.01), in part because of a greater
requirement for intravenous fluid support in the saline group
(1050 ml versus 275 ml; P = 0.06). There was a small but
statistically significant improvement in the arterial oxygen
tension/fraction of inspired oxygen ratio in the treatment
group at 24, 48 and 72 hours. In terms of clinical outcomes,
30-day mortality was 7/20 (35%) in the treatment arm and
9/20 (45%) in the placebo arm, and median ventilator-free
days over 30 days of follow up were 5.5 in the treatment arm
and 1.0 in the placebo arm. The authors’ well argued
discussion and the accompanying editorial [16] both
conclude that a larger randomized trial of this intervention is
warranted. Of note, this second study fails to answer whether
albumin alone is efficacious, or indeed whether low-dose
furosemide, necessitating saline resuscitation, is harmful.
They comment (as does the editorial) that the effects of
albumin remain unclear.
To add further murkiness to the issue, a timely laboratory
analysis of commercially available albumin solutions was
reported by Bar-Or and colleagues [17]. They found that a
high proportion of post-translational oxidation had occurred in
the commercial samples as compared with healthy human
serum. The quantity of this oxidation varied markedly between
manufacturers and within batches from the same
manufacturer. Thus, before any study claims a beneficial
effect from albumin they would appear to need to
demonstrate that they have analyzed what they have
administered.
And other antioxidants, scavengers and
inflammatory modulators?
Staying on the topic of antioxidants, a trial of N-acetylcysteine
in high-risk patients undergoing pump coronary artery bypass
graft surgery [18] has failed to demonstrate any benefit – a
further negative study for this agent. In contrast, ascorbate
(vitamin C) may yet prove to be a useful adjunct in managing
sepsis, if the results of the study reported by Tyml and
coworkers [19] in a rat model of sepsis translate into useful
outcomes in human trials. Another agent on the distant
horizon of sepsis interventions is chemically modified
tetracycline (an anti-inflammatory with no antimicrobial
properties), which appears to produce dramatic results in a
standard model of rat sepsis [20].
Finally, two partially contradictory observational studies into
the relationship between severity of disease and fatal
outcomes from sepsis, and levels of serum lipoproteins
[21,22] suggest that measuring total cholesterol and
quantifying its high-density and low-density fractions may
provide useful prognostic information. It appears that
lipoproteins may act as functionally important scavengers of
bacterial toxins and as ‘good guys’ in the seemingly ever-
expanding innate immune response. Finding low levels of
lipoproteins correlates with greater severity of illness and fatal
outcome, although the exact pattern is not clear from these
two studies. This may reflect different responses to varying
bacterial species (Neisseria meningitides [21] versus a mixed
group of pathogens, almost certainly excluding Neisseria
meningitides [22]). Although it is understandable to leap to
the conclusion that restoring lipoprotein levels to the normal
range will be of therapeutic benefit in sepsis, this is a path
often trodden in the past with a very poor record of success.
Nitric oxide: the end of lung therapy but a
newly discovered role in the stomach
The European experts have considered the evidence and
published their recommendations regarding the use of
inhaled nitric oxide (NO) [23]. In summary, they suggest that
with little evidence of efficacy, if any, except in the diagnosis
of reversible pulmonary hypertension, and in the light of
escalating costs, the use of inhaled NO – outside of well
designed clinical trials – cannot be defended. By contrast,
evidence is accumulating that NO plays an important role in
gastric mucosal health, demonstrating bactericidal activity
and increasing both mucosal blood flow and mucus
production [24]. The source of this miraculous molecule
appears to be nitrites in saliva [25]. In this study, Björne and
colleagues performed gastric tonometry for NO in healthy
volunteers and intubated critically ill patients. The level of NO
in healthy individuals was 21.6 parts per million (ppm; range
11.4–22.3 ppm) whereas in the patient group levels were
only 0.1 ppm (range 0.06–0.4 ppm). The patients had normal
levels of salivary nitrite and gastric infusion of nitrite
successfully increased intragastric NO levels, implying that
saliva is not reaching the stomach. Trials of intragastric nitrite421
are keenly awaited, but in the meantime any spare supplies of
NO for inhalational therapy could be redirected …?
Error
We all make mistakes, but few of us have a dedicated team
of watchers on our ICUs pointing out all our faults. One
institution did install such an arrangement and has reported
their sobering findings [26]. In this centre of excellence there
was a daily rate of 0.8 adverse events and 1.5 serious errors
per 10-bed critical care unit. Most errors were described as,
‘slips and lapses, in particular, failures to carry out intended
plans of action’. It would unfeasible to provide anything close
to this level of vigilance in ICUs routinely, but reducing the
incidence of errors by any and all means should be a priority.
And finally …
The eagerly awaited UK PAC-Man study has been reported
[27]. Yet again, a cornerstone of ICU practice wanes in the
light of our inability to demonstrate any benefit from its use, or
should it? The design of the trial was to ascertain the safety
of pulmonary artery catheters, which it did by demonstrating
no difference in the outcomes of patients randomly allocated
to have a pulmonary artery catheter or not. The majority of
patients allocated to the control arm had access to alternative
methods of cardiac output monitoring and no element of care
was protocolized. There was a 10% complication rate
associated with insertion, but the vast majority of these were
clinically insignificant. Hopefully, this should end the safety
debate and allow research resources to be directed toward
improving the haemodynamic care of critically ill patients.
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